drugset / Trial / NCT00252668

Study Evaluating the Combination of Etanercept and Methotrexate in Rheumatoid Arthritis Subjects

NCT00252668

Phase 4 Completed 300 enrolled Wyeth is now a wholly owned subsidiary of Pfizer
RandomizedParallel-groupOpen-labelTreatment

Summary

This study is an open label extension of a previously completed double-blind, randomized study comparing etanercept and methotrexate in subjects with active rheumatoid arthritis. All subjects will receive combination treatment with etanercept and methotrexate.

Timeline

Start
2004-06
Primary completion
Completion
2005-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic
Subject Methotrexate Small molecule

Indications